Even though several neutralizing antibodies against TNF-α have been recently approved for treating ulcerative colitis (UC), one of the major forms of IBD, their effectiveness in sustaining remission of the disease is only 17–40% [17,18,19,20], suggesting that the role and regulation of TNF-α signaling in colonic inflammation and wound healing is still poorly understood. This evidence concerns the gene TNF and ulcerative colitis.